TRAIL acts synergistically with iron oxide nanocluster-mediated magneto- and photothermia.
Apoptosis
/ drug effects
Cell Death
/ physiology
Cell Line, Tumor
Cell Survival
/ drug effects
Ferric Compounds
/ chemistry
Flow Cytometry
Humans
Hyperthermia, Induced
/ methods
Microscopy, Electron, Transmission
TNF-Related Apoptosis-Inducing Ligand
/ chemistry
Tumor Necrosis Factor-alpha
/ metabolism
TRAIL
apoptosis
iron oxide nanoclusters
magnetic hyperthermia
photothermal therapy
Journal
Theranostics
ISSN: 1838-7640
Titre abrégé: Theranostics
Pays: Australia
ID NLM: 101552395
Informations de publication
Date de publication:
2019
2019
Historique:
received:
04
05
2019
accepted:
09
06
2019
entrez:
20
9
2019
pubmed:
20
9
2019
medline:
1
9
2020
Statut:
epublish
Résumé
Targeting TRAIL (Tumor necrosis factor (TNF)-Related Apoptosis-Inducing Ligand) receptors for cancer therapy remains challenging due to tumor cell resistance and poor preparations of TRAIL or its derivatives. Herein, to optimize its therapeutic use, TRAIL was grafted onto iron oxide nanoclusters (NCs) with the aim of increasing its pro-apoptotic potential through nanoparticle-mediated magnetic hyperthermia (MHT) or photothermia (PT).
Identifiants
pubmed: 31534529
doi: 10.7150/thno.36320
pii: thnov09p5924
pmc: PMC6735372
doi:
Substances chimiques
Ferric Compounds
0
TNF-Related Apoptosis-Inducing Ligand
0
Tumor Necrosis Factor-alpha
0
ferric oxide
1K09F3G675
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5924-5936Déclaration de conflit d'intérêts
Competing Interests: The authors have declared that no competing interest exists.
Références
Acc Chem Res. 2009 Aug 18;42(8):1097-107
pubmed: 19476332
Mater Today (Kidlington). 2016 Apr;19(3):157-168
pubmed: 27524934
Small. 2015 May;11(20):2437-45
pubmed: 25644392
Int J Radiat Oncol Biol Phys. 1984 Jun;10(6):787-800
pubmed: 6547421
Sports Med Arthrosc Rev. 2009 Jun;17(2):112-26
pubmed: 19440139
Clin Immunol. 2006 Nov;121(2):159-76
pubmed: 16920030
Biomaterials. 2018 Sep;176:60-70
pubmed: 29860138
Mar Drugs. 2015 Nov 13;13(11):6884-909
pubmed: 26580630
ACS Nano. 2014 Apr 22;8(4):3192-201
pubmed: 24597847
Oncotarget. 2018 Feb 17;9(21):15566-15578
pubmed: 29643993
Nat Nanotechnol. 2009 Nov;4(11):710-1
pubmed: 19898521
Nanoscale. 2014 Aug 21;6(16):9494-530
pubmed: 25030381
Br J Cancer. 1998 May;77(9):1386-94
pubmed: 9652753
Angew Chem Int Ed Engl. 2007;46(8):1222-44
pubmed: 17278160
J Pharm Pharmacol. 2013 Jan;65(1):11-21
pubmed: 23215683
J Mol Recognit. 2016 Sep;29(9):406-14
pubmed: 26952193
ACS Nano. 2016 Feb 23;10(2):2436-46
pubmed: 26766814
Angew Chem Int Ed Engl. 2013 Oct 25;52(44):11526-9
pubmed: 24115553
J Mater Chem B. 2013 Mar 7;1(9):1326-1332
pubmed: 32260806
Cancer Lett. 2007 May 18;250(1):117-27
pubmed: 17141951
Cell Death Dis. 2018 Aug 29;9(9):874
pubmed: 30158588
Chem Rev. 2012 Apr 11;112(4):2323-38
pubmed: 22216932
Nat Rev Drug Discov. 2008 Sep;7(9):771-82
pubmed: 18758474
Theranostics. 2019 Feb 12;9(5):1288-1302
pubmed: 30867831
Nat Med. 2007 Sep;13(9):1070-7
pubmed: 17767167
Nanomedicine (Lond). 2015 Jul;10(14):2167-83
pubmed: 25959578
Cancer Lett. 2016 Dec 28;383(2):250-260
pubmed: 27725224
Methods Mol Biol. 2017;1557:19-31
pubmed: 28078579
Int J Mol Sci. 2018 Mar 02;19(3):
pubmed: 29498673
Nano Lett. 2015 Feb 11;15(2):891-5
pubmed: 25584433
J Mol Med (Berl). 2009 Oct;87(10):995-1007
pubmed: 19680616
Chem Commun (Camb). 2019 Apr 2;55(28):4055-4058
pubmed: 30875417
Oncol Rep. 2017 Jun;37(6):3635-3642
pubmed: 28440502
Haematologica. 2012 Jan;97(1):38-46
pubmed: 21933852
Pharmacol Rev. 2002 Dec;54(4):561-87
pubmed: 12429868
ACS Nano. 2014 Feb 25;8(2):1350-63
pubmed: 24401079
Neuro Oncol. 2013 Jan;15(1):29-40
pubmed: 23144078
Biochem Biophys Res Commun. 2009 Sep 4;386(4):645-9
pubmed: 19559008
J Mater Chem B. 2014 Feb 21;2(7):757-765
pubmed: 32261307
Cell Mol Life Sci. 2010 Sep;67(18):3115-30
pubmed: 20508968
Nanoscale. 2015 May 7;7(17):7885-95
pubmed: 25854197
Br J Pharmacol. 2013 Aug;169(8):1723-44
pubmed: 23638798
Cell Death Differ. 2007 Dec;14(12):2021-34
pubmed: 17703232
Nano Lett. 2013 Jun 12;13(6):2399-406
pubmed: 23659603
Acc Chem Res. 2011 Oct 18;44(10):883-92
pubmed: 21548618
Oncotarget. 2017 Feb 7;8(6):9974-9985
pubmed: 28039489
Int J Nanomedicine. 2007;2(4):707-14
pubmed: 18203437
J Mater Chem B. 2017 May 7;5(17):3154-3162
pubmed: 32263713
Proc Natl Acad Sci U S A. 2019 Mar 5;116(10):4044-4053
pubmed: 30760598
J Control Release. 2018 Jun 10;279:271-281
pubmed: 29684497
Adv Drug Deliv Rev. 2011 Aug 14;63(9):789-808
pubmed: 21447363
Genet Mol Res. 2015 Dec 28;14(4):18562-8
pubmed: 26782504
PLoS One. 2016 Feb 26;11(2):e0150031
pubmed: 26919720
Biochim Biophys Acta. 2013 Aug;1830(8):4254-64
pubmed: 23648413
Cell Death Differ. 2017 Mar;24(3):500-510
pubmed: 28186505
Adv Drug Deliv Rev. 2019 Jan 1;138:233-246
pubmed: 30414493
Adv Healthc Mater. 2016 May;5(9):1040-8
pubmed: 26990061
Cell Death Dis. 2015 Feb 12;6:e1633
pubmed: 25675293
PLoS One. 2009 Oct 02;4(10):e7240
pubmed: 19806207
PLoS One. 2012;7(5):e37376
pubmed: 22615995
Biomaterials. 2016 Oct;104:352-60
pubmed: 27487574
Nanoscale. 2017 May 11;9(18):5755-5768
pubmed: 28443893